InMed Pharmaceuticals (INM)
(Delayed Data from NSDQ)
$0.33 USD
0.00 (0.98%)
Updated May 21, 2024 03:59 PM ET
After-Market: $0.31 -0.02 (-5.83%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for InMed Pharmaceuticals Inc falls in the month of June.
All items in Millions except Per Share data.
6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 | 6/30/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 9 | 6 | 7 | 6 | 14 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 2 | 2 | 0 | 0 | 0 |
Other Current Assets | 1 | 1 | 1 | 0 | 0 |
Total Current Assets | 11 | 10 | 8 | 6 | 14 |
Net Property & Equipment | 1 | 1 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 2 | 2 | 1 | 1 | 1 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 14 | 13 | 10 | 8 | 15 |
Liabilities & Shareholders Equity | 6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 | 6/30/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 2 | 2 | 2 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 1 | 0 | 0 | 0 |
Total Current Liabilities | 2 | 3 | 2 | 2 | 1 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 2 | 4 | 2 | 2 | 1 |
Shareholders Equity | 6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 | 6/30/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 78 | 71 | 61 | 53 | 53 |
Capital Surplus | 36 | 32 | 22 | 18 | 17 |
Retained Earnings | -101 | -93 | -75 | -65 | -56 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 12 | 9 | 7 | 6 | 14 |
Total Liabilities & Shareholder's Equity | 14 | 13 | 10 | 8 | 15 |
Total Common Equity | 12 | 9 | 7 | 6 | 14 |
Shares Outstanding | 3.33 | 0.65 | 0.30 | NA | NA |
Book Value Per Share | 3.63 | 13.97 | 24.60 | 0.00 | 0.00 |
Fiscal Year End for InMed Pharmaceuticals Inc falls in the month of June.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 8 | 10 | 7 | 9 | 10 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 1 | 1 | 1 | 2 | 1 |
Other Current Assets | 1 | 1 | 0 | 1 | 1 |
Total Current Assets | 10 | 12 | 8 | 11 | 12 |
Net Property & Equipment | 1 | 1 | 1 | 1 | 1 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 2 | 2 | 2 | 2 | 2 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 13 | 15 | 11 | 14 | 15 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 1 | 1 | 2 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 2 | 2 | 1 | 2 | 2 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 1 | 1 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 2 | 2 | 1 | 2 | 2 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 81 | 80 | 78 | 78 | 78 |
Capital Surplus | 38 | 38 | 36 | 36 | 36 |
Retained Earnings | -107 | -105 | -104 | -101 | -101 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 11 | 13 | 10 | 12 | 12 |
Total Liabilities & Shareholder's Equity | 13 | 15 | 11 | 14 | 15 |
Total Common Equity | 11 | 13 | 10 | 12 | 12 |
Shares Outstanding | 6.06 | 5.67 | 3.30 | 3.30 | 3.30 |
Book Value Per Share | 1.83 | 2.25 | 2.90 | 3.66 | 3.75 |